Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: A propensity score-matched study

Blood

Volumn 125, Issue 6, 2015, Pages 924-929

  Kang, Matthew ^a   Alahmadi, Majed ^a   Sawh, Sonja ^b   Kovacs, Michael J ^a   Lazo Langner, Alejandro ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; CREATININE; DANAPAROID; FONDAPARINUX; ANTICOAGULANT AGENT; HEPARIN; POLYSACCHARIDE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; COHORT ANALYSIS; COMORBIDITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL ADMISSION; HUMAN; KAPLAN MEIER METHOD; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPENSITY SCORE; THROMBOSIS; CHEMICALLY INDUCED; COMPLICATION; HEMORRHAGE; MIDDLE AGED; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; MALE; MIDDLE AGED; POLYSACCHARIDES; PROPENSITY SCORE; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 84922357652     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-599498     Document Type: Article

References (50)

1. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996; 101(5): 502-507.
2. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999; 106(6): 629-635.
3. Walls JT, Curtis JJ, Silver D, Boley TM, Schmaltz RA, Nawarawong W. Heparin-induced thrombocytopenia in open heart surgical patients: sequelae of late recognition. Ann Thorac Surg. 1992; 53(5): 787-791.
4. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995; 332(20): 1330-1335.
5. Harenberg J, Jörg I, Fenyvesi T. Heparin-induced thrombocytopenia: pathophysiology and new treatment options. Pathophysiol Haemost Thromb. 2002; 32(5-6): 289-294.
6. Li ZQ, Liu W, Park KS, et al. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood. 2002; 99(4): 1230-1236.
7. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994; 93(1): 81-88.
8. Warkentin TE, Hayward CP, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994; 84(11): 3691-3699.
9. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006; 4(4): 759-765.
10. Pouplard C, Gueret P, Fouassier M, et al. Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost. 2007; 5(7): 1373-1379.
11. Cuker A, Arepally G, Crowther MA, et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost. 2010; 8(12): 2642-2650.
12. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012; 141(SUPPL. 2):e495S-530S.
13. Chong BH, Gallus AS, Cade JF, et al.; Australian HIT Study Group. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. Thromb Haemost. 2001; 86(5): 1170-1175.
14. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation. 1999; 100(6): 587-593.
15. Greinacher A, Völpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999; 99(1): 73-80.
16. Lewis BE, Wallis DE, Berkowitz SD, et al.; ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001; 103(14): 1838-1843.
17. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG; Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003; 163(15): 1849-1856.
18. Lubenow N, Eichler P, Lietz T, Farner B, Greinacher A. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood. 2004; 104(10): 3072-3077.
19. Magnani HN Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost. 1993; 70(4): 554-561.
20. Hein OV, von Heymann C, Diehl T, et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Ren Fail. 2004; 26(3): 297-303.
21. Hursting MJ, Alford KL, Becker JC, et al. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost. 1997; 23(6): 503-516.
22. Kiser TH, Jung R, MacLaren R, Fish DN. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy. 2005; 25(12): 1736-1745.
23. Smythe MA, Stephens JL, Koerber JM, Mattson JC. A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost. 2005; 11(4): 371-374.
24. Vargas Hein O, von Heymann C, Lipps M, et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Med. 2001; 27(4): 673-679.
25. Bauer KA, Hawkins DW, Peters PC, et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. Cardiovasc Drug Rev. 2002; 20(1): 37-52.
26. Baroletti S, Labreche M, Niles M, Fanikos J, Goldhaber SZ. Prescription of fondaparinux in hospitalised patients. Thromb Haemost. 2009; 101(6): 1091-1094.
27. Schindewolf M, Scheuermann J, Kroll H, et al. Application, tolerance and safety of fondaparinux therapy in a German hospital: a prospective singlecentre experience. Thromb Res. 2012; 129(1): 17-21.
28. Grouzi E, Kyriakou E, Panagou I, Spiliotopoulou I. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience. Clin Appl Thromb Hemost. 2010; 16(6): 663-667.
29. Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost. 2008; 99(1): 208-214.
30. Kuo KH, Kovacs MJ. Fondaparinux: a potential new therapy for HIT. Hematology. 2005; 10(4): 271-275.
31. Kuo KH, Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost. 2005; 93(5): 999-1000.
32. Greinacher A, Warkentin TE. Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. Thromb Res. 2006; 118(2): 165-176.
33. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986; 67(1): 27-30.
34. Kovacs MJ, Rodger M, Anderson DR, et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med. 2003; 138(9): 714-719.
35. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3(4): 692-694.
36. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999; 150(4): 327-333.
37. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998; 17(19): 2265-2281.
38. Austin PC An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011; 46(3): 399-424.
39. Austin PC A tutorial and case study in propensity score analysis: an application to estimating the effect of in-hospital smoking cessation counseling on mortality. Multivariate Behav Res. 2011; 46(1): 119-151.
40. R Core Team. (2012). R: A language and environment for statistical computing (Version 2.12.0). R foundation for statistical computing, Vienna, Austria. http://www.r-project.org/. Accessed October 17, 2012.
41. Thoemmes F. Propensity Score Matching in SPSS. Tubingen, Germany: University of Tubingen; 2011.http://sourceforge.net/projects/psmspss/.
42. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011; 173(6): 676-682.
43. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. Am J Epidemiol. 2006; 163(12): 1149-1156.
44. Newcombe RG Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998; 17(8): 857-872.
45. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health (Version 3.01). Atlanta, Georgia: Rollins School of Public Health, Emory University 2012. http://www.openepi.com.
46. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53(282): 457-481.
47. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50(3): 163-170.
48. Warkentin TE, Pai M, Sheppard JI, Schulman S, Spyropoulos AC, Eikelboom JW. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost. 2011; 9(12): 2389-2396.
49. Savi P, Chong BH, Greinacher A, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood. 2005; 105(1): 139-144.
50. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005; 106(12): 3791-3796.